GW Pharmaceuticals

Our vision is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet needs.
GW is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy.

Company Growth (employees)
Type
Public
HQ
Histon, GB
Founded
1998
Size (employees)
496 (est)
GW Pharmaceuticals was founded in 1998 and is headquartered in Histon, GB

GW Pharmaceuticals Office Locations

GW Pharmaceuticals has offices in Histon, London and Carlsbad
Histon, GB (HQ)
Vision Park
London, GB
1 Cavendish Pl
Carlsbad, US
210 5800 Armada Dr

GW Pharmaceuticals Financials and Metrics

GW Pharmaceuticals Financials

GW Pharmaceuticals's revenue was reported to be £10.3 m in FY, 2016 which is a 64% decrease from the previous period.
GBP

Revenue (FY, 2016)

10.3 m

Revenue growth (FY, 2015 - FY, 2016), %

(64%)

Gross profit (FY, 2016)

7.6 m

Gross profit margin (FY, 2016), %

74%

Net income (FY, 2016)

(63.7 m)

EBITDA (FY, 2016)

(82.9 m)

EBIT (FY, 2016)

(86.6 m)

Market capitalization (31-Oct-2017)

2.7 b

Closing share price (31-Oct-2017)

106.2

Cash (30-Sep-2016)

374.4 m
GW Pharmaceuticals's current market capitalization is $2.7 b.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

5.7 m11.8 m24.1 m30.7 m29.6 m33.1 m27.3 m30 m28.5 m10.3 m

Revenue growth, %

10%(5%)(64%)

Cost of goods sold

254 k249 k433 k752 k1.3 m839 k1.3 m2.1 m2.6 m2.7 m

Gross profit

5.4 m11.5 m23.7 m29.9 m28.3 m32.3 m26 m28 m25.9 m7.6 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(10.9 m)(8.2 m)1.5 m4.6 m2.7 m2.5 m(4.5 m)(14.7 m)(44.6 m)(63.7 m)

Cash From Operating Activities

(1.5 m)7.4 m1.2 m4.3 m2.4 m1.8 m(7.5 m)(12.6 m)(46.5 m)(84.6 m)

Cash From Financing Activities

62 k104 k6.3 m628 k1.4 m73 k18.3 m144.3 m128.4 m206.8 m

Net Change in Cash

2.5 m6.9 m6.5 m4.6 m3.1 m814 k8.7 m124.5 m64.2 m113.5 m
    GBPY, 2016

    Revenue/Employee

    26.5 k

    Financial Leverage

    1.1 x
    Show all financial metrics

    GW Pharmaceuticals Market Value History

    GW Pharmaceuticals's Web-traffic and Trends

    GW Pharmaceuticals News and Updates

    Corix Biosciences, Inc. (OTCQB: CXBS) - GW Pharmaceuticals (NASDAQ: GWPH) Should Acquire This

    This article is published in collaboration with Scutify, where you can find real-time markets a

    GW Pharmaceuticals Company Life and Culture

    You may also be interested in